MLTX — MoonLake Immunotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $2.66bn
- $2.12bn
- 38
- 31
- 52
- 35
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS/A | 10-K | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash | |||
Cash and Equivalents | |||
Short Term Investments | |||
Cash and Short Term Investments | 8.04 | 72.1 | 511 |
Net Total Receivables | 1.43 | 4.18 | 3.05 |
Prepaid Expenses | |||
Total Current Assets | 9.64 | 76.5 | 514 |
Net Property, Plant And Equipment | 0.046 | 0.332 | 3.95 |
Other Long Term Assets | |||
Total Assets | 9.68 | 76.8 | 527 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 21.1 | 7.67 | 9.97 |
Total Long Term Debt | |||
Total Debt | |||
Minority Interest | |||
Total Other Liabilities | |||
Total Funded Status | |||
Total Liabilities | 21.3 | 27.9 | 30.9 |
Non Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Treasury Stock | |||
Other Equity | |||
Total Equity | -11.6 | 48.9 | 496 |
Total Liabilities & Shareholders' Equity | 9.68 | 76.8 | 527 |
Total Common Shares Outstanding |